"10.1371_journal.pone.0124987","plos one","2015-05-08T00:00:00Z","Frits A Wijburg; Bernard Bénichou; Daniel G Bichet; Lorne A Clarke; Gabriela Dostalova; Alejandro Fainboim; Andreas Fellgiebel; Cassiano Forcelini; Kristina An Haack; Robert J Hopkin; Michael Mauer; Behzad Najafian; C Ronald Scott; Suma P Shankar; Beth L Thurberg; Camilla Tøndel; Anna Tylki-Szymańska; Uma Ramaswami","Academic Medical Center, University Hospital of Amsterdam, Amsterdam, The Netherlands; Genzyme Europe, Saint-Germain-en-Laye, France; Hôpital du Sacré-Cœur de Montréal and University of Montreal, Montreal, QC, Canada; University of British Columbia, Child and Family Research Institute, Vancouver, BC, Canada; Charles University Prague, General University Hospital Prague, Prague, Czech Republic; Hospital de Niños Ricardo Gutierrez, Hospital de Día Polivalente, Ciudad Autónoma de Buenos Aires, Argentina; University Medical Center Mainz, Mainz, Germany; Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil; Sanofi, Chilly-Mazarin, France; Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States of America; Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America; Department of Pathology, University of Washington, Seattle, Washington, United States of America; University of Washington School of Medicine, Seattle, Washington, United States of America; Emory University School of Medicine, Decatur, Georgia, United States of America; Department of Pathology, Genzyme, Framingham, Massachusetts, United States of America; Department of Pediatrics, Haukeland University Hospital, Bergen, Norway; Klinika Pediatrii, Żywienia i Chorób Metabolicznych Instytut Pomnik – Centrum Zdrowia Dziecka, Warsaw, Poland; Royal Free Hospital, London, United Kingdom","Conceived and designed the experiments: FAW UR RJH MM CT AT-S BB. Performed the experiments: FAW UR DGB LAC GD A. Fainboim A. Fellgiebel CF RJH MM BN CRS SPS CT AT-S. Analyzed the data: FAW UR A. Fellgiebel MM BN CT BB KAH BLT. Wrote the paper: FAW UR DGB LAC GD A. Fainboim A. Fellgiebel CF RJH MM BN CRS SPS CT AT-S BB KAH BLT. Patient recruitment: FAW UR DGB LAC GD A. Fainboim A. Fellgiebel CF RJH MM BN CRS SPS CT AT-S. Data acquisition: FAW UR DGB LAC GD A. Fainboim A. Fellgiebel CF RJH MM BN CRS SPS CT AT-S.","U.R. has read the journals policy and the authors of this manuscript have the following competing interests: F.A.W. and D.G.B. have received honoraria for presentations and board meetings, travel expenses to meetings and honoraria for consultancy work from Genzyme and Shire HGT, and have received unrestricted educational grants and research grants from Genzyme. L.C. has received speakers fees and travel support from Genzyme. B.B., B.L.T., and K.A.H. are full-time employees of Genzyme, the funder of this study. C.T. has received speakers fees and travel support from Genzyme and Shire HGT. R.J.H. consults with Genzyme and Shire HGT and has been an investigator in clinical trials sponsored by Genzyme, Shire HGT, and Amicus. These activities have been monitored and found to be in compliance with the conflict of interest policies at Cincinnati Childrens Hospital Medical Center. G.D. has received honoraria and grants for presentations and meetings from Genzyme and Shire HGT. A.F. has received honoraria for presentations and board meetings, and has received unrestricted educational grants and research grants from Genzyme and Shire HGT. M.M. is a member of the Genzyme-sponsored FDA-mandated Fabry Registry Board, has an investigator-initiated research grant from Genzyme, is a consultant to Genzyme for clinical trial design, and has received speakers fees and travel support from Genzyme. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies. A.T.S. has received honoraria for presentations and board meetings and travel expenses to meetings from Genzyme and Shire HGT. C.R.S. is a consultant to Genzyme and has received research funding and educational grants from Genzyme. S.P.S. has been a site primary investigator in clinical trials, received research support and educational grants sponsored by Genzyme, Shire, Protalix, Actelion and Amicus. S.P.S. has also received honorarium and travel support as speaker and for investigator meetings of Genzyme, Shire HGT and Protalix. These activities have been monitored and found to be in compliance with the conflict of interest policies at Emory University. B.N. has received research grants, speakers honoraria and travel support from Genzyme, is a consultant to Genzyme and Amicus, is on medical advisory board of Amicus, and received research grant from Roche. These interests have been reviewed and managed by the University of Washington Office of Research. U.R. has received research and travel grants and honoraria for lectures from Shire HGT and Genzyme. C.F. has been an investigator in clinical trials sponsored by Genzyme. The authors received no honoraria related to the development of this publication. A.F. has no conflicts of interest. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","05","Frits A Wijburg","FAW",18,TRUE,7,6,3,6,TRUE,TRUE,TRUE,5,"8;12;13;14;15",TRUE
